Axsome Therapeutics AXSM Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's accounts receivable?
- Axsome Therapeutics (AXSM) reported accounts receivable of $251.06M in Q1 2026.
- How has Axsome Therapeutics's accounts receivable changed year-over-year?
- Axsome Therapeutics's accounts receivable increased by 55.6% year-over-year, from $161.4M to $251.06M.
- What is the long-term trend for Axsome Therapeutics's accounts receivable?
- Over 3 years (2022 to 2025), Axsome Therapeutics's accounts receivable has grown at a 81.2% compound annual growth rate (CAGR), from $37.7M to $224.46M.
- What does accounts receivable mean?
- Money owed to the company by customers for products or services already provided.
- How do you interpret accounts receivable?
- An increase relative to revenue may signal collection issues, while a decrease indicates efficient cash conversion.
- How does accounts receivable compare across companies?
- Commercial-stage peers show higher receivables; clinical-stage companies often show minimal balances until product launch.